|
|
|
| Effect of methotrexate combined with uterine artery embolization for treating cesarean scar pregnancy and its influence on their subsequent pregnancy |
| 1.Huiji District People's Hospital, Zhengzhou, Henan Province, 450000； 2.The First Affiliated Hospital of Zhengzhou University； 3.The Third People's Hospital of Henan Province |
|
|
|
|
Abstract To analyze the clinical effect of methotrexate (MTX) combined with uterine artery embolization (UAE) for treating cesarean scar pregnancy (CSP) of the women, and to study its influence on their subsequent pregnancy. Methods: 115 women with CSP were selected as study subjects, and were divided into group A (women used MTX) and group B (women used MTX combined with UAE) according to the principle of voluntary selection of the women from February 2013 to March 2017. The clinical efficacy, the ovarian function indexes, and the situation of subsequent pregnancy of the women were compared between groups. Results: The amount of blood loss during curettage (48.3±8.6 ml), the time of hospital stay (15.3±5.3 d), the time of blood β-HCG level returned to normal (20.4±7.8 d), and the time of mass disappearance (30.7±8.3 d) of the women in group B were significant lower than those of the women in group A (P＜0.05). There were no significant differences in the time of hysterectomy (30.7±9.5min vs 31.2±8.6min) and the incidence of complications (14.3% vs 11.5%) of the women between the two groups (P＞0.05). There were no significant differences in the serum levels of anti-Muller's tube hormone, follicle-stimulating hormone, luteinizing hormone, and estradiol, the clinical pregnancy rate, the duration of no contraception, and the rates of spontaneous abortion, recurrent CSP, and placental abnormality in 3 and 6 months after surgery of the women between the two groups (P＞0.05). Conclusion: The clinical efficacy of MTX combined with UAE for treating women with CSP is superior to MTX treatment alone without adverse effects on the subsequent pregnancy.
|
|
|
|
|
|
|
|
|
